Drug Search Results
More Filters [+]

Nendratareotide uzatansine

Alternative Names: nendratareotide uzatansine, pen-221, pen221, pen 221
Latest Update: 2024-05-10
Latest Update Note: PubMed Publication

Product Description

A miniaturized drug conjugate composed of a peptide analog of somatostatin that targets the somatostatin receptor 2 (SSTR2) and is conjugated, through a cleavable linker, to the microtubule-binding cytotoxic maytansinoid DM1 (mertansine), with potential anti-tumor activity.

Mechanisms of Action: SSTR Modulator

Novel Mechanism: Yes

Modality: Peptide/Protein

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Tarveda
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Nendratareotide uzatansine

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Neuroendocrine Carcinoma|Thymus Cancer|Small Cell Lung Cancer|Neuroendocrine Tumors|Pancreatic Cancer|Large Cell Carcinoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

PEN-221-001

P2

Completed

Neuroendocrine Tumors|Neuroendocrine Carcinoma|Small Cell Lung Cancer

2020-07-31

Phase 1/2a to assess PEN-221 in somatostatin receptor 2 expressing advanced cancers

P2

Unknown status

Small Cell Lung Cancer|Thymus Cancer|Large Cell Carcinoma|Pancreatic Cancer|Neuroendocrine Carcinoma

2019-02-09

Recent News Events